Immuno-Oncology

From novel Target Identification to Functional Assays:
we have the complete solution

invitro-magnifyglass.png

Quickly Identify the Right Target for Your Therapy

Cancer immunotherapy is coming of age as a treatment paradigm, however, development of new immunotherapeutics still faces many challenges. Testing new immuno-oncology compounds in vitro, before moving to the in vivo setting, has proved challenging for many new drugs such as biological agents.

CrownBio offers a wide range of assays and platforms for in vitro testing of immuno-oncology agents, including core immunophenotyping, functional assays, and technologies for the regulation of the tumor microenvironment, allowing you to move with confidence to the next phase of drug development.

In Vitro Immunophenotyping and Cell Profiling

CrownBio’s core in vitro immunophenotyping and cell profiling platform provides a comprehensive range of assays:

  • FACS and IHC for immuno-oncology agent characterization
  • Immune cell purification for subset enrichment
  • Cytokine profiling – Luminex assay, ELISA/ELISPOT to quantify the frequency of cytokine-producing cells
  • T cell receptor sequencing for biomarker ID and diagnostic development
  • Cell proliferation assays with isolated immune cells to evaluate your compound’s cytotoxic potential

Functional Assays

CrownBio offers a variety of functional assays to investigate your compound’s ability to activate the immune system, regulate the tumor microenvironment, or induce immune cell-dependent cancer cell death. Whether your compounds target cells from the innate or adaptive immune system, we have in vitro assays to test their efficacy, including for the most recently developed IDO inhibitors.

Antigen Presentation and Immune System Activation Assays

CrownBio and our partners offer a variety of assays for measuring the immunogenicity of experimental proteins and peptides in vitro. Our assays are customized to target immune cells, including T and B cells, natural killer cells, macrophages, and dendritic cells, as well as tumor cells.

T Cell Targets and Activation

  • T cell proliferation
  • Recalled T cell function assay
  • Target expression profiling on cell subsets (resting and activated)
  • Screening assays for enhanced proliferation and survival (MLR, antigen driven systems)
  • Screening for the ability to reverse T cell exhaustion
  • Suppression of Treg function
  • Modulation of differentiation and cytokine profile
  • Immune cell migration assay

Macrophages and Dendritic Cell Targets

  • Target expression profiling on subsets (resting vs activated)
  • Screening for modulation of M1/M2/MDSC (e.g. differentiation)
  • Screening for modulation of tumor conditional response (phenotype and cytokine/chemokine production)
  • Effects on antigen presentation

NK Cell Targets

  • Target expression on NK cells
  • Modulation of activation and killing

B Cell Targets

  • Target expression profiling on B cell subsets (resting and activated)
  • Modulation of antibody production
  • Modulation of antigen presenting cell function and cytokine release

Tumor Targets

  • Target expression profiling on subsets
  • Effects on antigen presentation/killing assays
  • Modulation of checkpoint ligand expression
  • Modulation of tumor derived immune modulating factors (e.g.eicosanoids, chemokines, cytokines)
  • Direct cytotoxicity

Regulation of Tumor Environment

Microbiome Sequencing

Microbiota play an important role in determining an organisms response to anticancer treatment, even in tumors far from the gastrointestinal tract, possibly because of their pro-inflammatory properties which activate the immune system.

In order to gain insights into the complex interaction between the microbiome and cancer therapy, CrownBio performs fecal collection and microbiome profiling (16S rRNA sequencing) to compare gut microbiomes across our syngeneic models, which we can correlate with response to therapy.

Immune Cell Mediated Cancer Cell Killing

Enhancement of effector cell cancer killing functions can be achieved by appropriately priming the immune system with targeted antibodies.

At CrownBio we have experience with a variety of immune cell mediated cancer cell killing strategies involving natural killer and effector T cells. Our range of assays includes:

  • ADCC
  • CDC
  • T cell killing – LDH assay
  • NK mediated cell killing assay (FACS based)

Novel Immuno-Oncology Target Identification

Immuno-oncology is a fast paced field, and the identification and validation of novel targets is vital to new agent development.

At CrownBio we are constantly enhancing our in vitro immuno-oncology platforms, and now provide a variety of assays to evaluate your IDO and TDO inhibitor effects on human and murine cancer cell proliferation in vitro, including validated tryptophan catabolism assays.

IDO/TDO, as tryptophan catabolizing enzymes, are overexpressed on tumor cells, and have been shown to assist cancer cells in immune evasion, providing key enzymes for targeting with immunotherapeutic inhibitors.

Contact us today for free expert advice to support all of your immuno-oncology research needs.

Quick Facts

Posters

  • AACR 2015 1038 - Cell-based Screening Identifes Gene Expression Signature Correlated with Sensitivity to PI3KmTOR Dual Inhibitor BEZ235
  • AACR 2014 3440 - Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to MEK Inhibitor Trametinib

Related Services

Blog Posts